本季度信息
根据公告，锦欣生殖2026年上半年实现营收13.73亿元，同比提升6.6%。同期，经调整净利润录得1.48亿元，较上年同期增长79.8%。毛利率亦由30.4%提升至37.4%。经营活动所得现金净额为2.48亿元，较去年同期的2.68亿元下降约7.6%。
成本结构方面，销售及分销费用为0.92亿元，同比增长23.9%，占营收比重约6.7%；研发投入约0.12亿元，同比增长31.3%，占营收比重约0.9%；管理费用为2.14亿元，小幅下降2.4%，占营收比重约15.6%。
业务分项
根据公告，核心的辅助生殖及相关服务收入约11.60亿元，同比增长7.5%。海外业务实现收入4.98亿元，同比增长22.8%。女性健康相关服务及其他业务收入2.32亿元，同比增长7.6%。产科及相关医疗服务1.89亿元，同比下降1.8%。公告称，辅助生殖板块的增长主要受海外市场需求增加与国内核心医疗网络稳定运营带动，而女性健康业务也在国内多地实现协同提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.